Different genotypes are responsible for the normal Russell viper venom assays seen in some cases of congenital factor X deficiency

American Journal of Hematology

Volumn 83, Issue 11, 2008, Pages 884-885

  Girolami, Antonio ^a   Scapin, Margherita ^a   Scarparo, Pamela ^a   Vettore, Silvia ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10; PHOSPHATIDYLETHANOLAMINE; VIPER VENOM;

BLEEDING; BLOOD CLOTTING FACTOR 10 DEFICIENCY; BLOOD CLOTTING TIME; EXON; GENE MUTATION; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LETTER; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTHROMBIN TIME; SNAKE;

FACTOR X; FACTOR X DEFICIENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MUTATION; PHENOTYPE; PROTHROMBIN TIME;

EID: 55549124574     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21276     Document Type: Letter

References (19)

1. Girolami A, Scarparo P, Scandellari R, Allemand E. Congenital factor X deficiencies with a defect only or predominantly in the extrinsic or in the intrinsic system: A critical evaluation. Am J Hematol, 2008;83:668-671.
2. Girolami A, Molaro G, Lazzarin M, et al. A new congenital haemorrhagic condition due to the presence of an abnormal factor X (factor X Friuli). A study of large kindred. Br J Haematol 1970;19:179-192.
3. Cooper DN, Millar DS, Wacey A, et al. Inherited factor X deficiency: Molecular genetics and pathophysiology. Thromb Haemost 1997;78:161-172.
4. Uprichard J, Perry DJ. Factor X deficiency. Blood Rev 2002;16:97-110.
5. MacFarlane RG.Hemostasis. In: Biggs R, editor. Human Blood Coagulation, Hemostasis and Thrombosis. Oxford: Blackwell Scientific Publications; 1972. pp 543.
6. Bertina RM, Alderkamp GJ, de Nogy E. A variant of factor X that is defective only in extrinsic coagulation. Thromb Haemost 1981;46:88a.
7. De Stefano V, Leone G, Ferrelli R, et al. Factor X Roma: A congenital factor X variant defective at different degrees in the intrinsic and extrinsic activation. Br J Haematol 1998;69:387-391.
8. Forberg E, Huhmann I, Jimenez-Boj E, Watzke HH. The impact of Glu102Lys on the factor X function in a patient with a doubly homozygous factor X deficiency (Gla14Lys and Glu102Lys). Thromb Haemost 2000;85:234-238.
9. Girolami A, Vicariotto M, Ruzza G, et al. Factor X Padua: A new congenital factor X abnormality. Acta Haematol 1985;73:31-36.
10. 2+ binding site of factor X protease domain appears to be responsible for the defect in the extrinsic pathway activation of factor X Padua. Clin Appl Thromb Haemost 2004;10:5-8.
11. James HL, Girolami A, Fair DS. Molecular defect in coagulation factor X Friuli results from a substitution of Serine for Proline at position 343. Blood 1991;77:317-323.
12. Nora RE, Bell WR, Noe DA, Sholar PW. Normal partial thromboplastin time and associated spindle cell thymoma. Ann J Med 1985;79:122-126.
13. Odom MW, Leone G, De Stefano V, et al. Five novel point mutations: Two causing haemophilia B and three causing factor X deficiency. Mol Cell Probes 1994;8:63-65.
14. Parkin JD, Madaras F, Sweet B, Castaldi PA. A further inherited variant of coagulation factor X. Aust N Z J Med 1974;4:561-564.
15. red FX deficiency. Thromb Haemost 2002;88:236-241.
16. Simioni P, Vianello F, Kalafatis M, et al. A dysfunctional factor X (factor X San Giovanni Rotondo) present at homozygous and double heterozygous level: Identification of a novel microdeletion (delC556) and missense mutation (Lys(408)->Asn) in the factor X gene. A study of an Italian family. Thromb Res 2001;101:219-230.
17. Sun P, Hata J, Bauer J, Haibach C, et al. A functional factor X deficiency. Am J Haematol 1995;48:1-4.
18. Watzke HH, Lechner K, Roberts HR, et al. Molecular defect (Gla+14-Lys) and its functional consequences in a hereditary factor X deficiency (factor X "Vorarlberg"). J Biol Chem 1990;265:11982-11989.
19. Bezeaud A, Miyata T, Helley D, et al. Functional consequences of the Ser 334 - Pro mutation in a human factor X variant (factor X Marseille). Eur J Biochem 1995;234:140-147.